Our research findings indicate that in osimertinib-resistant NSCLC, there is an upregulation of PIM1 expression, which is sufficient to induce the inactivation (phosphorylation) of GSK3β. This evidence concerns the gene GSK3B and non-small cell lung carcinoma.